I sit down to write this introduction after my first full month as Executive Director. It has been a month of learning – about the programme, our projects, and our organisation, but above all about the work of everyone involved in IHI and their commitment to the initiative.
The articles in this month’s newsletter highlight how the ‘innovative’ in Innovative Health Initiative doesn’t just refer to our research and the outcomes, but also to the way we are driving new collaborations across sectors and between stakeholder groups. The new IHI project PREDICTOM exemplifies how we are applying this approach to the challenge of finding methods for the early diagnosis of Alzheimer’s. The partners come from medical technology, artificial intelligence, medicine, aging research, and from academia, healthcare, and small and large companies.
PREDICTOM also demonstrates another strength of IHI – the way it builds on the experiences and successes of IMI. PREDICTOM joins an impressive portfolio of projects addressing Alzheimer’s and other neurological disorders. We report on one of these, EPND, which has discovered novel molecular subtypes in Alzheimer’s disease and is establishing a large, transnational reference dataset.
The strength of this ecosystem we are creating via our projects is evident in a steady stream of new publications from long-finished projects, and this month I enjoyed reading about the outcomes from the CANCER-ID project. I hope you will find it as interesting as I did.
Niklas Blomberg, IHI Executive Director
